Quantcast
Last updated on April 17, 2014 at 12:34 EDT

Latest Cetuximab Stories

2013-11-18 08:29:07

HILDEN, Germany, and GERMANTOWN, Maryland, November 18, 2013 /PRNewswire/ -- - Collaboration aims to use QIAGEN's companion diagnostic development capabilities to create a companion diagnostic paired with a novel oncology compound from Lilly - New partnership builds on Lilly-QIAGEN framework agreement for development of advanced diagnostic tests to guide treatment with innovative therapies - Third project follows...

2013-10-31 08:33:35

However, Changes in Treatment Practices Via Improved Originator Biologics Threaten Biosimilar Uptake, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. and European oncologists will cautiously adopt biosimilar monoclonal antibodies initially; only a minority of oncologists say they will...

2013-10-21 12:27:53

Initial data from ongoing clinical study presented by MD Anderson Cancer Center and Trovagene at AACR-NCI-EORTC International Conferences highlights promise of urine-based, cell-free diagnostics SAN DIEGO, Oct. 21, 2013 /PRNewswire/ -- Trovagene Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced that study findings presented today demonstrate that the company's novel, non-invasive oncogene mutation detection technology can be a clinically useful...

2013-10-21 10:08:34

Patients with cancers driven by the protein KRAS, which are particularly hard to treat, may benefit from small molecules that attach to and disrupt the function of a KRAS-containing protein complex, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. Mutant forms of the protein KRAS are found in approximately 30 percent of all cancers. They are responsible for many of the hallmarks of these...

2013-10-17 08:29:17

LAUSANNE, Switzerland, MECHELEN, Belgium and BARCELONA, Spain, October 17, 2013 /PRNewswire/ -- Today Biocartis and Hospital del Mar announced their licence agreement on the EGFR biomarker for colon cancer. This agreement enables Biocartis to develop a new colon cancer test, whereby a specific EGFR mutation can be rapidly and accurately detected in patients, which will enable doctors to recommend personalised therapy. Innovative platforms and tests for cancer diagnosis...

2013-10-02 08:29:47

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, October 2, 2013 /PRNewswire/ -- Today, Investors' Reports announced new research reports highlighting Celgene Corporation (NASDAQ: CELG), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Nektar Therapeutics (NASDAQ: NKTR), and Zalicus Inc. (NASDAQ: ZLCS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings...

2013-09-30 14:06:50

Research institutes, regulators and the pharmaceutical industry are urged to cooperate to develop new approaches to testing cancer drugs, in order to bring the revolution in personalized medicine to patients across Europe, says the European Society for Medical Oncology. It has become clear in recent years that each patient's cancer has individual characteristics that are potentially amenable to "personalized" treatments that target those characteristics. But there is still a great deal of...

2013-09-30 13:54:55

Improves treatment and survival Identifying the molecular profile of a tumor where the primary site is unknown is crucial to the choice of treatment, the 2013 European Cancer Congress (ECC2013), will hear on Monday. In up to five percent of all cancers, the site of the primary tumor is unknown and the disease is not diagnosed until it is at an advanced stage, when the cancer has metastasized (spread to other parts of the body). Until recently, the choice of treatment has been based on...

2013-09-28 08:20:24

First study to find patients with unfavorable risk profile at 12 weeks have worse prognosis and should be considered for alternative treatments RARITAN, N.J., Sept. 28, 2013 /PRNewswire/ -- Janssen Diagnostics, LLC announced today results from a study presented at the European Cancer Congress in Amsterdam, Netherlands, that demonstrated circulating tumor cell (CTC) enumeration using CELLSEARCH®, along with lactate dehydrogenase (LDH) as part of a composite biomarker panel, was an...

2013-09-28 04:20:17

Trial Evaluated Nearly 1,000 Patients With Metastatic Colorectal Cancer THOUSAND OAKS, Calif., Sept. 28, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 ASPECCT ('763) trial comparing Vectibix(®) (panitumumab) to Erbitux(®) (cetuximab) for the treatment of wild-type KRAS metastatic colorectal cancer in patients who have not responded to chemotherapy. The study met its primary endpoint, demonstrating that panitumumab was non-inferior to cetuximab...